Skip to content
Companies

Artelo Biosciences

Lipid-signaling drugs for cachexia, pain and anxiety

Raised to date

$11.7M

of $11.7M offered across 4 Form D filings

Investors
1
Last filed
Apr 6, 2026

About

Artelo Biosciences, Inc. is a clinical-stage pharmaceutical company that develops therapeutics by modulating lipid-signaling pathways, including the endocannabinoid system. Its pipeline comprises three proprietary candidates targeting cancer-related cachexia, neuropathic pain, and anxiety and depression. The company was founded in 2017, trades on Nasdaq under ARTL, and operates from Solana Beach, California with additional offices in Ireland and the UK.

A portfolio built entirely around lipid-signaling modulation, pairing a first-in-class small-molecule FABP5 inhibitor with a peripherally selective cannabinoid receptor agonist and a proprietary CBD cocrystal.

Funding

$11M round, first sold Mar 2026$11M soldMar 2026JunSep
Now
  • EquityFiled Apr 6, 2026Form D
    $11M/ $11M
  • DebtFiled Mar 27, 2026Form D
    $315K/ $315K
  • DebtFiled Mar 27, 2026Form D
    $113K/ $113K
  • DebtFiled Mar 27, 2026Form D
    $237K/ $237K

Product

ART26.12

Small-molecule drug candidate

A potent and selective oral inhibitor of fatty acid binding protein 5 (FABP5), an intracellular lipid transport protein, developed as a peripherally acting non-opioid analgesic. Its lead indication is chemotherapy-induced peripheral neuropathy (CIPN), with additional interest in other neuropathic pain, psoriasis, breast, prostate and cervical cancer, and generalized anxiety.

  • Selective FABP5 inhibitor, first-in-class mechanism
  • Peripherally acting, non-opioid
  • Completed Phase 1 single-ascending-dose and food-effect studies

Built for

Oncologists, pain specialists, and the patients they treat, reached through pharmaceutical partners and payers once candidates are approved.

People on file